FIGIJ and NASPAG Advocacy Statement Supporting Fertility Preservation for Pediatric and Adolescent Patients Receiving Gonadotoxic Therapy
J Pediatr Adolesc Gynecol
.
2024 Oct;37(5):457-459.
doi: 10.1016/j.jpag.2024.06.001.
Epub 2024 Jun 14.
Authors
Judith S Simms-Cendan
1
,
Yasmin Jayasinghe
2
,
Angela Aguilar
3
,
Clara Di Nunzio
4
,
Ellen Rome
5
,
Mariela Orti
6
,
Anastasia Vatopoulou
7
,
Michalina Drejza
8
,
Nichole Tyson
9
,
Megan Sumida
10
,
Mary Romano
11
Affiliations
1
University of Miami School of Medicine, Miami, Florida. Electronic address:
[email protected]
.
2
University of Melbourne Royal Womens College, Melbourne, Australia.
3
University of the Philippines Manila College of Medicine and the Philippine General Hospital, Manila, Philippines.
4
Instituto Universitario CEMIC Escuela de Medicina, Buenos Aires, Argentina.
5
Cleveland Clinic Lerner College of Medicine of CWRU, Cleveland, OH.
6
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
7
University of Ioannina Faculty of Medicine, Ioannina, Greece.
8
Cambridge University Hospitals NHS Foundation Trust, Cambridge, England.
9
Stanford University School of Medicine, Stanford, CA.
10
Baylor College of Medicine, Houston, Texas.
11
Vanderbilt University School of Medicine Nashville, Tennessee.
PMID:
38880287
DOI:
10.1016/j.jpag.2024.06.001
No abstract available
Publication types
Practice Guideline
MeSH terms
Adolescent
Antineoplastic Agents / adverse effects
Child
Female
Fertility Preservation* / methods
Humans
Neoplasms / drug therapy
Patient Advocacy
Substances
Antineoplastic Agents